Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin for extensive disease small cell lung cancer.
Phase of Trial: Phase II
Latest Information Update: 21 Apr 2017
At a glance
- Drugs Amrubicin (Primary) ; Carboplatin (Primary) ; Irinotecan (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 24 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network record (UMIN000008970).
- 12 Oct 2012 New source identified and integrated (University Hospital Medical Information Network record UMIN000008970).
- 24 Sep 2012 Status changed from not yet recruiting to recruiting according to the University Hospital Medical Information Network record (UMIN000008970).